ADAP Adaptimmune Therapeutics plc

5.34
-0.07  -1%
Previous Close 5.41
Open 5.38
Price To book 2.25
Market Cap 499.27M
Shares 93,496,000
Volume 158,841
Short Ratio 0.73
Av. Daily Volume 287,947

SEC filingsSee all SEC filings

  1. 8-K - Current report 17849241
  2. CT ORDER - Confidential treatment order 17844865
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17829147
  4. 8-K - Current report 17828490
  5. DEF 14A - Other definitive proxy statements 17796474

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated 2H 2017.
NY-ESO T-cell therapy
Synovial sarcoma - cancer
Further trials planned for 2H 2016
NY-ESO T-cell therapy
Ovarian cancer
Pivotal trial placed on clinical hold due to non-safety issues. Hold released November 2016. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy
Myxoid round cell liposarcoma (MRCLS)
Further trials planned for 1H 2017.
NY-ESO T-cell therapy
Myeloma
Phase 1/2 initiated November 2015. Data are due 2017.
NY-ESO T-cell therapy
Non-small cell lung cancer (NSCLC)

Latest News

  1. Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
  2. Adaptimmune Reports First Quarter 2017 Financial Results
  3. Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
  4. Adaptimmune to Report First Quarter 2017 Financial Results on May 10, 2017
  5. Adaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference
  6. Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
  7. Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
  8. Adaptimmune Therapeutics Plc :ADAP-US: Earnings Analysis: 2016 By the Numbers : March 28, 2017
  9. Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit
  10. Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
  11. Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
  12. Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
  13. Edited Transcript of ADAP earnings conference call or presentation 13-Mar-17 12:00pm GMT
  14. Adaptimmune Broadens Executive Team
  15. Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results

SEC Filings

  1. 8-K - Current report 17849241
  2. CT ORDER - Confidential treatment order 17844865
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17829147
  4. 8-K - Current report 17828490
  5. DEF 14A - Other definitive proxy statements 17796474
  6. CT ORDER - Confidential treatment order 17771894
  7. PRE 14A - Other preliminary proxy statements 17756867
  8. 8-K - Current report 17753993
  9. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 17746469
  10. 8-K - Current report 17741235